Search

Your search keyword '"Villafuerte FC"' showing total 66 results

Search Constraints

Start Over You searched for: Author "Villafuerte FC" Remove constraint Author: "Villafuerte FC"
66 results on '"Villafuerte FC"'

Search Results

1. S0859, an N-cyanosulphonamide inhibitor of sodium-bicarbonate cotransport in the heart

2. Ischemic changes in exercise ECG in a hypertensive subject acutely exposed to high altitude. Possible role of a high-altitude induced imbalance in myocardial oxygen supply-demand.

3. Exercise pathophysiology in patients with chronic mountain sickness exercise in chronic mountain sickness.

4. pH-regulated Na+ influx into the mammalian ventricular myocyte: the relative role of Na+-H+ exchange and Na+-HCO3-co-transport.

5. The Effects of Nocturnal Hypoxemia on Cognitive Performance in Andean Highlanders.

6. Altitude illnesses.

7. Functional EPAS1 / HIF2A missense variant is associated with hematocrit in Andean highlanders.

8. Long noncoding RNA HIKER regulates erythropoiesis in Monge's disease via CSNK2B.

9. Lifelong exposure to high-altitude hypoxia in humans is associated with improved redox homeostasis and structural-functional adaptations of the neurovascular unit.

10. Preserved peak exercise capacity in Andean highlanders with excessive erythrocytosis both before and after isovolumic hemodilution.

11. Editorial: Stroke and infarction at high-altitude.

12. Isovolemic hemodilution in chronic mountain sickness acutely worsens nocturnal oxygenation and sleep apnea severity.

13. Time Domains of Hypoxia Responses and -Omics Insights.

14. Editorial: Hypoxia in cardiovascular disease.

15. Comparing high versus low-altitude populations to test human adaptations for increased ventilation during sustained aerobic activity.

16. High-Altitude Erythrocytosis: Mechanisms of Adaptive and Maladaptive Responses.

17. ARID1B, a molecular suppressor of erythropoiesis, is essential for the prevention of Monge's disease.

18. Global Reach 2018: sympathetic neural and hemodynamic responses to submaximal exercise in Andeans with and without chronic mountain sickness.

19. Global Research Expedition on Altitude-related Chronic Health 2018 Iron Infusion at High Altitude Reduces Hypoxic Pulmonary Vasoconstriction Equally in Both Lowlanders and Healthy Andean Highlanders.

20. Sub-maximal aerobic exercise training reduces haematocrit and ameliorates symptoms in Andean highlanders with chronic mountain sickness.

21. Global REACH 2018: volume regulation in high-altitude Andeans with and without chronic mountain sickness.

22. Global Reach 2018: Nitric oxide-mediated cutaneous vasodilation is reduced in chronic, but not acute, hypoxia independently of enzymatic superoxide formation.

23. Global REACH 2018: Influence of excessive erythrocytosis on coagulation and fibrinolytic factors in Andean highlanders.

24. Potential Protective Effect from COVID-19 Conferred by Altitude: A Longitudinal Analysis in Peru During Full Lockdown.

25. Peruvian research: striving for the highest standards.

26. Global REACH 2018: dysfunctional extracellular microvesicles in Andean highlander males with excessive erythrocytosis.

27. Protective role of estrogen against excessive erythrocytosis in Monge's disease.

28. Global REACH 2018: Andean highlanders, chronic mountain sickness and the integrative regulation of resting blood pressure.

29. The 2018 Global Research Expedition on Altitude Related Chronic Health (Global REACH) to Cerro de Pasco, Peru: an Experimental Overview.

30. Global REACH 2018: renal oxygen delivery is maintained during early acclimatization to 4,330 m.

31. Office and Ambulatory Arterial Hypertension in Highlanders: HIGHCARE-ANDES Highlanders Study.

33. Adaptive Potential of the Heme Oxygenase/Carbon Monoxide Pathway During Hypoxia.

34. Global Reach 2018 Heightened α-Adrenergic Signaling Impairs Endothelial Function During Chronic Exposure to Hypobaric Hypoxia.

35. Relationships Between Chemoreflex Responses, Sleep Quality, and Hematocrit in Andean Men and Women.

36. High-Altitude Hypoxia Decreases Plasma Erythropoietin Soluble Receptor Concentration in Lowlanders.

37. Global REACH: Assessment of Brady-Arrhythmias in Andeans and Lowlanders During Apnea at 4330 m.

38. Increased hypoxic proliferative response and gene expression in erythroid progenitor cells of Andean highlanders with chronic mountain sickness.

39. Global Reach 2018: reduced flow-mediated dilation stimulated by sustained increases in shear stress in high-altitude excessive erythrocytosis.

40. The overlooked significance of plasma volume for successful adaptation to high altitude in Sherpa and Andean natives.

41. The Genetic Architecture of Chronic Mountain Sickness in Peru.

42. Global REACH 2018: High Blood Viscosity and Hemoglobin Concentration Contribute to Reduced Flow-Mediated Dilation in High-Altitude Excessive Erythrocytosis

43. Genetic variants at the EGLN1 locus associated with high-altitude adaptation in Tibetans are absent or found at low frequency in highland Andeans.

44. Excessive Erythrocytosis and Cardiovascular Risk in Andean Highlanders.

45. Upward Shift and Steepening of the Blood Pressure Response to Exercise in Hypertensive Subjects at High Altitude.

46. Adaptive Servoventilation as Treatment for Central Sleep Apnea Due to High-Altitude Periodic Breathing in Nonacclimatized Healthy Individuals.

47. Blood pressure response to six-minute walk test in hypertensive subjects exposed to high altitude: effects of antihypertensive combination treatment.

48. Plasma soluble erythropoietin receptor is decreased during sleep in Andean highlanders with Chronic Mountain Sickness.

49. Chronic Mountain Sickness: Clinical Aspects, Etiology, Management, and Treatment.

50. SENP1, but not fetal hemoglobin, differentiates Andean highlanders with chronic mountain sickness from healthy individuals among Andean highlanders.

Catalog

Books, media, physical & digital resources